Allergy Therapeutics PLC
LSE:AGY

Watchlist Manager
Allergy Therapeutics PLC Logo
Allergy Therapeutics PLC
LSE:AGY
Watchlist
Price: 6.25 GBX -0.79% Market Closed
Market Cap: 297.9m GBX
Have any thoughts about
Allergy Therapeutics PLC?
Write Note

Allergy Therapeutics PLC
Common Shares Outstanding

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Allergy Therapeutics PLC
Common Shares Outstanding Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Common Shares Outstanding CAGR 3Y CAGR 5Y CAGR 10Y
Allergy Therapeutics PLC
LSE:AGY
Common Shares Outstanding
ÂŁ4.8B
CAGR 3-Years
95%
CAGR 5-Years
50%
CAGR 10-Years
28%
GlaxoSmithKline PLC
LSE:GSK
Common Shares Outstanding
ÂŁ4.1B
CAGR 3-Years
0%
CAGR 5-Years
-4%
CAGR 10-Years
-2%
AstraZeneca PLC
LSE:AZN
Common Shares Outstanding
$1.6B
CAGR 3-Years
6%
CAGR 5-Years
3%
CAGR 10-Years
2%
Verona Pharma PLC
NASDAQ:VRNA
Common Shares Outstanding
$654.6m
CAGR 3-Years
11%
CAGR 5-Years
44%
CAGR 10-Years
N/A
Hikma Pharmaceuticals PLC
LSE:HIK
Common Shares Outstanding
$221.1m
CAGR 3-Years
-2%
CAGR 5-Years
-2%
CAGR 10-Years
1%
Dechra Pharmaceuticals PLC
LSE:DPH
Common Shares Outstanding
ÂŁ113.9m
CAGR 3-Years
2%
CAGR 5-Years
2%
CAGR 10-Years
3%
No Stocks Found

Allergy Therapeutics PLC
Glance View

Market Cap
297.9m GBX
Industry
Pharmaceuticals

Allergy Therapeutics Plc is a biotechnology company. The company is headquartered in Worthing, West Sussex and currently employs 601 full-time employees. The company went IPO on 2004-10-11. The firm is focused on the treatment and diagnosis of allergic disorders, including immunotherapy vaccines. Its segments include Central Europe, which include segments, such as Germany, Austria, Switzerland and the Netherlands; Southern Europe, which includes Italy, Spain and Other; the United Kingdom, and Rest of World. The company sells both injectable and sublingual allergen-specific immunotherapies. Its pipeline candidates include Grass MATA MPL, Birch MATA MPL, Ragweed MATA MPL, Trees MATA MPL and Peanut SCIT. Its vaccine candidates outside allergy include disease areas, including cancer, asthma, atopic dermatitis and psoriasis. Its products include Pollinex, Pollinex Quattro, Oralvac, Acarovac Plus, Venomil, VLP Peanut and ImmunoBON.

AGY Intrinsic Value
4.33 GBX
Overvaluation 31%
Intrinsic Value
Price

See Also

What is Allergy Therapeutics PLC's Common Shares Outstanding?
Common Shares Outstanding
4.8B GBP

Based on the financial report for Dec 31, 2023, Allergy Therapeutics PLC's Common Shares Outstanding amounts to 4.8B GBP.

What is Allergy Therapeutics PLC's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
28%

Over the last year, the Common Shares Outstanding growth was 223%. The average annual Common Shares Outstanding growth rates for Allergy Therapeutics PLC have been 95% over the past three years , 50% over the past five years , and 28% over the past ten years .

Back to Top